ombitasvir; paritaprevir; ritonavir · Abbvie · NDA 207931
Technivie
Earliest generic entry, as listed
13 Apr 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8691938.
Listed patents · 6 unexpired
7 Orange Book listing rows for 6 patents, including 1 pediatric extension. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 8691938 | drug substance, drug product · sets the listed date | 13 Apr 2032 |
| US 8420596 | drug substance, drug product | 10 Oct 2031 |
| US 8420596 listing row | drug substance, drug product | 10 Apr 2031 |
| US 8420596 listing row | pediatric extension | 10 Oct 2031 |
| US 8686026 | drug product | 9 Jun 2031 |
| US 9044480 | use U-1638 | 10 Apr 2031 |
| US 9006387 | use U-1687 | 10 Jun 2030 |
| US 8642538 | drug substance, drug product, use U-1638 | 10 Sep 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207931 · 001 · RLD · discontinued | tablet, oral | 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 13 Apr 2032 |